Syn2bio S.A. (WSE:S2B)

Market Cap	427.90M
Revenue	n/a
Net Income	n/a
EPS	n/a
Shares Out	8.73M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	45,805
Open	48.80
Previous Close	48.70
Day's Range	48.60 - 51.43
52-Week Range	26.20 - 56.50
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Jun 25, 2026

About Syn2bio

Syn2bio S.A., a biotechnology company, engages in the research and commercialization of Cardiac Marker, a radiopharmaceutical for diagnostic testing of heart disease in the field of myocardial perfusion. The company’s flagship project is the cardiotracer project, a radiopharmaceutical designed for testing myocardial perfusion and diagnosis of coronary artery disease. Additionally, it operates The Centre for Research on New Compounds, a unit engaged in the search for new pharmaceutical compounds and their further study, registration, and market ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2025
• Country: Poland
• Stock Exchange: Warsaw Stock Exchange
• Ticker Symbol: S2B

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Jul 4, 2026

Data Sources Report a data error